120564-14-9

Basic information

• Product Name: (S)-O-[(2,2-DIMETHYL-1,3-DIOXOLAN-4-YL)METHYL]-HYDROXYAMINE HYDROHLORIDE
• Synonyms: (S)-O-[(2,2-DIMETHYL-1,3-DIOXOLAN-4-YL)METHYL]-HYDROXYAMINE HYDROHLORIDE;(S)-o-[(2,2-dimethyl-2,3-dioxolan-4-yl)methyl]-hydroxyamine HCl;(S)-O-[(2,2-DIMEHTYL-1,3-DIOXOLAN-4-YL)METHYL]-HYDROXYAMINE HYDROHLORIDE
• CAS NO: 120564-14-9
• Molecular Formula: C₆H₁₃NO₃
• Molecular Weight: 185.64914
• Mol File: 120564-14-9.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 220.2±15.0 °C(Predicted)
• Appearance: /
• Density: 1.048±0.06 g/cm3(Predicted)
• PKA: 4.07±0.70(Predicted)
• CAS DataBase Reference: (S)-O-[(2,2-DIMETHYL-1,3-DIOXOLAN-4-YL)METHYL]-HYDROXYAMINE HYDROHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-O-[(2,2-DIMETHYL-1,3-DIOXOLAN-4-YL)METHYL]-HYDROXYAMINE HYDROHLORIDE(120564-14-9)
• EPA Substance Registry System: (S)-O-[(2,2-DIMETHYL-1,3-DIOXOLAN-4-YL)METHYL]-HYDROXYAMINE HYDROHLORIDE(120564-14-9)

Safety Data

• Hazardous Substances Data: 120564-14-9(Hazardous Substances Data)

Usage

General Description

(S)-O-[(2,2-DIMETHYL-1,3-DIOXOLAN-4-YL)METHYL]-HYDROXYAMINE HYDROHLORIDE is a chemical compound that is commonly used in scientific research and pharmaceutical development. It is a hydrochloride salt form of (S)-O-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-hydroxylamine, which is a derivative of hydroxylamine. (S)-O-[(2,2-DIMETHYL-1,3-DIOXOLAN-4-YL)METHYL]-HYDROXYAMINE HYDROHLORIDE has shown potential as a reagent in the synthesis of various organic compounds, as well as in the study of biological processes and biochemical pathways. It is important to handle this chemical with care and adhere to safety precautions, as it can pose health risks if mishandled or improperly used.

Upstream product

• 14347-78-5 1,2-O-isopropylidene-D-glycerol 
• 22323-82-6 (S)-(+)-(2,2-dimethyl-[1,3]dioxolan-4-yl)methanol 
• 76679-39-5 [(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl trifluoromethanesulfonate 
• 131068-34-3 (R)-2-(2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-isoindole-1,3-dione 
• 60-34-4 methylhydrazine 
• 131068-35-4 (S)-N-<(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy>phthalimide 

Downstream Products

• 1009335-79-8 3-(2-chloro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide 
• 1009335-81-2 3-(2,6-difluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide 
• 1009335-82-3 3-(2,5-difluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide 
• 1009335-87-8 7-bromo-3-(2-fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide 
• 1009335-89-0 5-(2-fluoro-4-iodo-phenylamino)-furo[2,3-d]pyrimidine-6-carboxylic acid ((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide 
• 1009335-96-9 7-chloro-3-(2-fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide 
• 391212-52-5 N-{[(R)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy}-3,4-difluoro-2-[(2-fluoro-4-iodo-phenyl)amino]benzamide 
• 1026989-63-8 (R)-N-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-6-(2-fluoro-4-iodophenylamino)-1-(fluoromethyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 
• 1026989-85-4 C₁₉H₂₂FIN₄O₆ 
• 1009335-76-5 3-(4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide 
• 1009335-75-4 3-(2-fluoro-4-iodo-phenylamino)-furo[2,3-c]pyridine-2-carboxylic acid ((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide 
• 1009335-74-3 3-(2-fluoro-4-bromo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide 
• 1009335-72-1 3-(2-fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide 

Relevant articles and documents

Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof

The present disclosure relates to a) crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide; b) pharmaceutical compositions comprising one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, one or more pharmaceutically acceptable carriers; c) methods of treating a tumor a cancer, or a Rasopathy disorder by administering one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to a subject in need thereof, and methods of producing essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide.

TOPICAL FORMULATIONS

Provided herein are gelled topical formulations for the treatment of skin diseases comprising: a) a MEK inhibitor; b) one or more organic solvents in an amount of about 70% to about 99% by weight; and c) a gelling agent; wherein the one or more organic solvents are selected from the group consisting of C2-6 alcohol, a C2-6 alkylene glycol, a di-(C2-6 alkylene) glycol, a polyethylene glycol, C1-3 alkyl-(OCH2CH2)1-5-OH, DMSO, ethyl acetate, acetone, N-methyl pyrrolidone, benzyl alcohol, glycerin, and an oil; the gelling agent is hydroxypropyl cellulose having a molecular weight ranging from about 40,000 Dato about 2,500,000 Da; and wherein the gelled topical formulation has a viscosity of from 1 to 25,000 cps; and DMSO, when present, is combined with at least one other of said organic solvents such that DMSO is present in an amount of less than 50% by weight.

ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS

Provided herein are compounds and pharmaceutical compositions thereof for treating a birthmark in a subject in need thereof, wherein the compound is according to any one of formula (1), (II), (III), (IV), and (V). wherein X1, X2, X3, R1, R2, R2a, R13, R13a, R23, R23a, R23b, R33, R33a, R33b, R43, R43a, R51, R53, R53a, R53b, bond "a", and subscript n are described herein.